Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aytu Biopharma, Inc

NASDAQ: AYTU · Life Sciences · 4 alerts · CIK 1385818

Share price
$1.82Close, Nov 16
Market cap
$19.8M
Shares outstanding
10.87MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aytu Biopharma, Inc filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Aytu Biopharma Q1 2026 Results: Net Loss of $3.88M

Aytu BioPharma reported significant warrant reclassifications from liability to equity following amendments in March 2026. The company maintains a $3.8 million Employee Retention Credit accrual and continues to manage debt through an Eclipse Business Capital loan agreement, while focusing on its ADHD and Pediatric portfolios.

Key figure
Net loss $3.88M
4:07 PM ET 8-K
Financial Results

Aytu Biopharma Financial Results

Aytu BioPharma reported fiscal 2026 fourth quarter net revenue of $16.1 million, a 6.4% increase year-over-year, driven by the commercial launch of EXXUA which generated $3.9 million in the quarter. For the full fiscal year 2026, net revenue was $57.6 million with a net loss of $14.3 million, as the company prioritized investments in its EXXUA launch over its legacy ADHD and pediatric portfolios.

Term
FY2026
Earnings call
Sep 22, 2026, 4:30 PM ET

“Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence in this exciting opportunity.”

Josh Disbrow, Chief Executive Officer of Aytu

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.